A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluarouracil (5FLI), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC).

被引：0
|
作者：
Casado, E
Folprecht, G
Paz-Ares, L
Rojo, F
Köhne, CH
Cortes-Funes, H
Vauthier, JM
Zacharchuk, C
Baselga, J
Tabernero, J
机构：
[1] Vall Hebron Univ Hosp, Barcelona, Spain
[2] Univ Klinik Carl Gustav Carus, Dresden, Germany
[3] Hosp Univ Doce Octubre, Madrid, Spain
[4] Wyeth Oncol, Paris, France
[5] Wyeth Oncol, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3543
引用
收藏
页码：255S / 255S
页数：1
相关论文
共 4 条
  • [1] The irreversible EGFR tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (ACC): A phase I/IIa pharmacokinetic and serial skin and tumor pharmacodynamic study
    Folprecht, Gunnar
    Tabernero, Josep
    Paz-Ares, Luis
    Baselga, Jose
    Cortes-Funes, Hernan
    Casado, Esther
    Rojo, Federico
    Vauthier, Jean-Michel
    Zacharchuk, Charles
    Koehne, Claus-Henning
    ANNALS OF ONCOLOGY, 2004, 15 : 85 - 85
  • [2] Phase I pharmacokinetic/pharmacodynamic study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor tyrosine kinase, in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in first-line treatment of patients with metastatic colorectal cancer
    Folprecht, Gunnar
    Tabernero, Josep
    Koehne, Claus-Henning
    Zacharchuk, Charles
    Paz-Ares, Luis
    Rojo, Federico
    Quinn, Susan
    Casado, Esther
    Salazar, Ramon
    Abbas, Richat
    Lejeune, Chantal
    Marimon, Irene
    Andreu, Jordi
    Ubbelohde, Ulrike
    Cortes-Funes, Hernan
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2008, 14 (01) : 215 - 223
  • [3] Appropriate schedule of oral tegafur / uracil (UFT) in combination with irinotecan (CPT-11) and bolus 5-FU / l-leucovorin (LV) in patients (pts) with metastatic colorectal cancer (MCRC): A phase I study
    Chayahara, N.
    Tamura, T.
    Miki, I.
    Okuno, T.
    Kamigaki, T.
    Nishisaki, H.
    Inoue, Y.
    Maeda, T.
    Sakaeda, T.
    Azuma, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [4] A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC).
    Baselga, J.
    Schöffski, P.
    Rojo, F.
    Dumez, H.
    Ramos, F. J.
    Macarulla, T.
    Cajal, R.
    Kisker, O.
    Van Oosterom, A.
    Tabernero, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 122S - 122S
1